Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

CD20-positive Hematological Malignancies × Injections, Subcutaneous × 1 year × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 3 Multiple Myeloma 2 Squamous Cell Carcinoma of Head and Neck 1 Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer 1 Patient Preference 1 Inflammatory Breast Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 CD20-positive Hematological Malignancies 1 Bile Duct Neoplasms 1 Advanced Cancers 1

Interventions

Injections, Subcutaneous 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07110194 2025-08-07

Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positive Hematological Malignancies

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Not yet recruiting

CD20-positive Hematological Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon ⚡